Evotec’s partner Roche provides initial update from Phase IIb trial in Alzheimer’s disease
Evotec partner Roche reported initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for treatment of Alzheimer’s disease. In this study, Sembragiline failed to demonstrate benefit on the primary endpoint after 52 weeks of treatment. June 30, 2015